cefalexin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antibiotics, cefalosporanic acid derivatives	571	15686-71-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: cefalexin hydrochloride cephalexin cefalexin cephacillin cephalexin anhydrous cephalexin hydrochloride cephalexin hydrate cefalexin HCl cephalexin HCl	A semisynthetic cephalosporin antibiotic with antimicrobial activity similar to that of CEPHALORIDINE or CEPHALOTHIN, but somewhat less potent. It is effective against both gram-positive and gram-negative organisms. Molecular weight: 347.39 Formula: C16H17N3O4S CLOGP: -1.84 LIPINSKI: 0 HAC: 7 HDO: 3 TPSA: 112.73 ALOGS: -3.07 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

cefalexin hydrochloride
cephalexin
cefalexin
cephacillin
cephalexin anhydrous
cephalexin hydrochloride
cephalexin hydrate
cefalexin HCl
cephalexin HCl

A semisynthetic cephalosporin antibiotic with antimicrobial activity similar to that of CEPHALORIDINE or CEPHALOTHIN, but somewhat less potent. It is effective against both gram-positive and gram-negative organisms.

Molecular weight: 347.39
Formula: C16H17N3O4S
CLOGP: -1.84
LIPINSKI: 0
HAC: 7
HDO: 3
TPSA: 112.73
ALOGS: -3.07
ROTB: 4

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
2	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	12 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	91 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	192.00 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	90 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.21 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	3.90 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.85 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	0.57 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Jan. 4, 1971	FDA	SHIONOGI INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	1091.81	10.87	1064	32370	249946	50321744
Cross sensitivity reaction	218.36	10.87	72	33362	1897	50569793
Type IV hypersensitivity reaction	209.62	10.87	74	33360	2408	50569282
Cellulitis	95.09	10.87	169	33265	70629	50501061
Loss of employment	85.37	10.87	34	33400	1552	50570138
Drug ineffective	82.53	10.87	273	33161	819060	49752630
Rash maculo-papular	68.10	10.87	86	33348	26555	50545135
Pemphigus	66.65	10.87	3	33431	120163	50451527
Synovitis	65.85	10.87	4	33430	123861	50447829
Injury	64.65	10.87	116	33318	48809	50522881
Urinary tract infection	58.90	10.87	298	33136	223722	50347968
Oesophageal spasm	58.10	10.87	29	33405	2267	50569423
Systemic lupus erythematosus	54.44	10.87	13	33421	140609	50431081
Hand deformity	53.98	10.87	3	33431	100196	50471494
Infusion related reaction	51.16	10.87	24	33410	169533	50402157
Glossodynia	50.38	10.87	8	33426	115561	50456129
Oesophageal pain	47.22	10.87	27	33407	2775	50568915
Joint swelling	44.62	10.87	58	33376	245228	50326462
Emotional distress	44.48	10.87	73	33361	28590	50543100
Pericarditis	40.47	10.87	3	33431	78686	50493004
Toxicity to various agents	39.94	10.87	49	33385	212450	50359240
Arthropathy	38.29	10.87	29	33405	157877	50413813
Lymphoedema	38.01	10.87	38	33396	9084	50562606
Urinary tract discomfort	36.02	10.87	11	33423	224	50571466
Rash	36.00	10.87	444	32990	437027	50134663
Cholecystitis chronic	34.39	10.87	37	33397	9632	50562058
Acute generalised exanthematous pustulosis	33.20	10.87	35	33399	8903	50562787
Completed suicide	32.25	10.87	24	33410	131865	50439825
Cystitis	31.47	10.87	82	33352	44482	50527208
Oedema	31.46	10.87	110	33324	70071	50501619
Chronic kidney disease	29.97	10.87	75	33359	39696	50531994
Uterine perforation	29.11	10.87	28	33406	6387	50565303
Alveolar osteitis	29.09	10.87	11	33423	436	50571254
Treatment failure	28.85	10.87	29	33405	137608	50434082
Bronchomalacia	28.20	10.87	9	33425	213	50571477
Hepatic enzyme increased	27.61	10.87	30	33404	137350	50434340
Rheumatoid arthritis	26.59	10.87	59	33375	202491	50369199
Deep vein thrombosis	26.30	10.87	107	33327	73197	50498493
Hepatitis infectious mononucleosis	26.29	10.87	7	33427	85	50571605
Pigment nephropathy	26.15	10.87	6	33428	37	50571653
Intentional overdose	25.76	10.87	5	33429	62499	50509191
Anxiety	25.72	10.87	203	33231	177403	50394287
Limb injury	25.45	10.87	47	33387	20203	50551487
Urticaria	25.14	10.87	159	33275	129402	50442288
Animal scratch	24.57	10.87	12	33422	895	50570795
Alopecia	24.21	10.87	82	33352	244965	50326725
Tunnel vision	24.04	10.87	11	33423	708	50570982
Depression	23.91	10.87	189	33245	165234	50406456
Bronchitis	23.51	10.87	133	33301	104026	50467664
Familial periodic paralysis	23.50	10.87	6	33428	61	50571629
Bladder pain	22.72	10.87	14	33420	1650	50570040
General physical health deterioration	22.61	10.87	37	33397	142397	50429293
Contraindicated product administered	22.45	10.87	40	33394	148918	50422772
Hallucination	21.66	10.87	74	33360	46583	50525107
Hepatic steatosis	21.63	10.87	49	33385	24335	50547355
Agitation neonatal	21.02	10.87	9	33425	494	50571196
Toxic epidermal necrolysis	20.68	10.87	44	33390	20948	50550742
Gallbladder disorder	19.97	10.87	38	33396	16704	50554986
Poor feeding infant	19.56	10.87	7	33427	237	50571453
Therapeutic product effect incomplete	19.49	10.87	19	33415	91496	50480194
Drug intolerance	19.22	10.87	77	33357	219027	50352663
Off label use	19.10	10.87	211	33223	474215	50097475
Amniotic cavity infection	19.05	10.87	11	33423	1152	50570538
Bronchopulmonary aspergillosis allergic	18.80	10.87	11	33423	1180	50570510
Wound complication	18.48	10.87	15	33419	2735	50568955
Implant site haematoma	17.86	10.87	5	33429	74	50571616
Immunoglobulins decreased	17.74	10.87	10	33424	1000	50570690
Overdose	17.68	10.87	24	33410	99703	50471987
Diarrhoea	17.14	10.87	509	32925	587967	49983723
Nephrolithiasis	16.96	10.87	56	33378	34637	50537053
Sleep apnoea syndrome	16.93	10.87	44	33390	23824	50547866
Dysuria	16.70	10.87	49	33385	28455	50543235
Gastric disorder	16.56	10.87	50	33384	29498	50542192
Intentional product use issue	16.35	10.87	16	33418	76902	50494788
Migraine	16.25	10.87	95	33339	75185	50496505
Staphylococcal infection	16.10	10.87	56	33378	35560	50536130
Type I hypersensitivity	16.01	10.87	13	33421	2372	50569318
Vanishing bile duct syndrome	15.98	10.87	8	33426	629	50571061
Paranasal sinus discomfort	15.41	10.87	14	33420	2972	50568718
Abscess drainage	15.28	10.87	7	33427	452	50571238
Nasal polyps	15.23	10.87	13	33421	2541	50569149
Product dose omission issue	15.22	10.87	187	33247	183651	50388039
Complement factor C4 increased	15.15	10.87	5	33429	132	50571558
Pruritus	15.04	10.87	267	33167	283301	50288389
Polymyalgia rheumatica	14.88	10.87	13	33421	2623	50569067
Foetal heart rate decreased	14.80	10.87	5	33429	142	50571548
Discomfort	14.68	10.87	31	33403	108349	50463341
Sinus pain	14.50	10.87	12	33422	2249	50569441
Appetite disorder	14.46	10.87	19	33415	6095	50565595
Multiple lentigines syndrome	14.45	10.87	5	33429	153	50571537
Anhedonia	14.43	10.87	24	33410	9500	50562190
Coma	14.35	10.87	10	33424	56869	50514821
Purpura senile	14.33	10.87	7	33427	522	50571168
Wound secretion	14.27	10.87	15	33419	3802	50567888
Morbid thoughts	14.17	10.87	7	33427	535	50571155
Therapy interrupted	14.14	10.87	37	33397	20115	50551575
Abdominal pain upper	14.04	10.87	164	33270	159145	50412545
Delirium	13.87	10.87	4	33430	38188	50533502
Hidradenitis	13.76	10.87	11	33423	1964	50569726
Ear congestion	13.62	10.87	11	33423	1992	50569698
Skin infection	13.57	10.87	27	33407	12264	50559426
Ureteric obstruction	13.37	10.87	10	33424	1618	50570072
Umbilical cord around neck	13.35	10.87	5	33429	193	50571497
Skin cancer	13.34	10.87	23	33411	9371	50562319
Cholelithiasis	13.27	10.87	55	33379	37918	50533772
Liposuction	13.14	10.87	3	33431	18	50571672
Developmental hip dysplasia	13.06	10.87	9	33425	1282	50570408
Clostridium difficile colitis	12.89	10.87	33	33401	17709	50553981
Retroperitoneal haematoma	12.88	10.87	12	33422	2631	50569059
Therapy cessation	12.73	10.87	42	33392	25969	50545721
Arthritis infective	12.70	10.87	17	33417	5552	50566138
Procedural pain	12.50	10.87	28	33406	13804	50557886
Clostridium difficile infection	12.38	10.87	41	33393	25398	50546292
Genital ulceration	12.29	10.87	6	33428	447	50571243
Loss of personal independence in daily activities	12.27	10.87	17	33417	70033	50501657
Meconium in amniotic fluid	12.22	10.87	5	33429	245	50571445
Ecthyma	12.18	10.87	5	33429	247	50571443
Anaphylactic reaction	12.17	10.87	69	33365	53986	50517704
Drug abuse	12.09	10.87	13	33421	59833	50511857
Helicobacter duodenal ulcer	12.08	10.87	3	33431	27	50571663
Bronchiectasis	11.85	10.87	23	33411	10260	50561430
Muscle haemorrhage	11.73	10.87	12	33422	2946	50568744
Skin laceration	11.63	10.87	33	33401	18809	50552881
Vertigo positional	11.47	10.87	11	33423	2500	50569190
Malignant neoplasm progression	11.47	10.87	17	33417	68107	50503583
Tarsal tunnel syndrome	11.30	10.87	6	33428	533	50571157
Swelling	11.27	10.87	82	33352	200790	50370900
Rhabdomyolysis	11.04	10.87	6	33428	39021	50532669
Diabetic retinal oedema	10.94	10.87	5	33429	321	50571369

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	140.21	13.10	172	14663	68234	29491458
Cellulitis	83.86	13.10	109	14726	45731	29513961
Rash	69.57	13.10	231	14604	189588	29370104
Clostridium test positive	39.79	13.10	20	14815	2097	29557595
Pruritus	37.29	13.10	136	14699	116713	29442979
Drug tolerance decreased	32.20	13.10	15	14820	1331	29558361
Clostridium difficile infection	32.03	13.10	40	14795	16101	29543591
Localised infection	31.94	13.10	37	14798	13779	29545913
Venolymphatic malformation	30.15	13.10	6	14829	23	29559669
Drug interaction	29.90	13.10	33	14802	197352	29362340
Drug abuse	29.34	13.10	3	14832	79880	29479812
Urinary tract infection	29.04	13.10	91	14744	72263	29487429
Skin infection	27.10	13.10	24	14811	6503	29553189
Urticaria	26.96	13.10	74	14761	54586	29505106
Circumoral oedema	26.66	13.10	6	14829	46	29559646
Renal hypoplasia	25.14	13.10	6	14829	61	29559631
Limb injury	24.96	13.10	27	14808	9328	29550364
Erythema	24.93	13.10	89	14746	75517	29484175
Rash pruritic	24.70	13.10	42	14793	22321	29537371
Joint swelling	24.29	13.10	67	14768	49563	29510129
Cross sensitivity reaction	23.94	13.10	12	14823	1250	29558442
Gut fermentation syndrome	22.73	13.10	4	14831	6	29559686
Kounis syndrome	22.39	13.10	13	14822	1816	29557876
Biliary sepsis	22.18	13.10	9	14826	571	29559121
Type IV hypersensitivity reaction	21.79	13.10	11	14824	1163	29558529
Skin laceration	21.29	13.10	27	14808	11035	29548657
Stevens-Johnson syndrome	20.94	13.10	33	14802	16464	29543228
Toxicity to various agents	19.39	13.10	36	14799	173625	29386067
Haemorrhoids thrombosed	18.80	13.10	6	14829	189	29559503
Therapy interrupted	18.61	13.10	22	14813	8364	29551328
Alveolar osteitis	18.47	13.10	5	14830	87	29559605
Allergy test positive	18.22	13.10	4	14831	27	29559665
Arthropathy	18.14	13.10	36	14799	21518	29538174
Perineal abscess	18.09	13.10	6	14829	214	29559478
Skin necrosis	18.01	13.10	17	14818	4995	29554697
Peripheral swelling	17.67	13.10	71	14764	63668	29496024
Swollen tongue	17.64	13.10	26	14809	12240	29547452
Mucormycosis	17.60	13.10	17	14818	5141	29554551
Retinal degeneration	17.36	13.10	7	14828	437	29559255
Urinary tract discomfort	17.33	13.10	5	14830	111	29559581
Treatment failure	17.21	13.10	49	14786	36890	29522802
Polyomavirus-associated nephropathy	17.20	13.10	14	14821	3382	29556310
General physical health deterioration	16.90	13.10	16	14819	102841	29456851
Lip haemorrhage	16.89	13.10	8	14827	737	29558955
Fungal skin infection	16.81	13.10	12	14823	2386	29557306
Renal injury	16.69	13.10	23	14812	10179	29549513
Neovascular age-related macular degeneration	16.58	13.10	5	14830	130	29559562
Skin ulcer	16.50	13.10	32	14803	18808	29540884
Clostridium difficile colitis	16.18	13.10	26	14809	13186	29546506
Multiple allergies	15.85	13.10	11	14824	2091	29557601
Middle ear effusion	15.73	13.10	7	14828	558	29559134
Skin lesion	15.60	13.10	31	14804	18541	29541151
Hypersensitivity vasculitis	15.60	13.10	13	14822	3244	29556448
Angioedema	15.52	13.10	43	14792	31872	29527820
Factor V inhibition	15.36	13.10	5	14830	168	29559524
Animal scratch	14.79	13.10	5	14830	189	29559503
Renal tubular necrosis	14.65	13.10	26	14809	14289	29545403
Herpes simplex	14.62	13.10	15	14820	4875	29554817
Urethral injury	14.40	13.10	4	14831	77	29559615
Tubulointerstitial nephritis	14.28	13.10	29	14806	17614	29542078
Pyogenic granuloma	14.03	13.10	5	14830	222	29559470
Mean platelet volume increased	14.03	13.10	6	14829	435	29559257
Skin cancer	13.72	13.10	19	14816	8449	29551243
Arthritis	13.46	13.10	35	14800	24984	29534708
Rheumatoid factor negative	13.17	13.10	7	14828	823	29558869

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	819.31	10.85	857	38351	236958	64222566
Type IV hypersensitivity reaction	232.53	10.85	85	39123	3337	64456187
Cross sensitivity reaction	230.16	10.85	84	39124	3283	64456241
Cellulitis	145.65	10.85	228	38980	93429	64366095
Rash	96.71	10.85	540	38668	458009	64001515
Loss of employment	78.68	10.85	33	39175	1874	64457650
Urinary tract infection	63.57	10.85	294	38914	231302	64228222
Rash maculo-papular	62.89	10.85	107	39101	46919	64412605
Oesophageal spasm	60.73	10.85	30	39178	2495	64457029
Toxicity to various agents	57.93	10.85	82	39126	363431	64096093
Oesophageal pain	56.22	10.85	31	39177	3232	64456292
Injury	53.15	10.85	110	39098	55882	64403642
Urticaria	48.81	10.85	198	39010	147119	64312405
Pruritus	47.63	10.85	339	38869	312061	64147463
Drug abuse	45.69	10.85	12	39196	132362	64327162
Urinary tract discomfort	45.15	10.85	14	39194	328	64459196
Synovitis	42.83	10.85	5	39203	99085	64360439
Oedema	42.72	10.85	138	39070	91797	64367727
Alveolar osteitis	42.25	10.85	14	39194	408	64459116
Limb injury	41.85	10.85	61	39147	23444	64436080
Emotional distress	39.24	10.85	75	39133	35963	64423561
Clostridium difficile infection	39.06	10.85	75	39133	36088	64423436
Drug ineffective	38.83	10.85	326	38882	839921	63619603
Lymphoedema	38.04	10.85	38	39170	9867	64449657
Infusion related reaction	36.41	10.85	28	39180	164439	64295085
Clostridium test positive	35.06	10.85	25	39183	4090	64455434
Acute generalised exanthematous pustulosis	35.04	10.85	43	39165	14015	64445509
Cholecystitis chronic	34.51	10.85	35	39173	9252	64450272
Animal scratch	33.80	10.85	15	39193	978	64458546
Uterine perforation	33.47	10.85	28	39180	5792	64453732
Completed suicide	33.40	10.85	53	39155	224361	64235163
Skin infection	32.74	10.85	43	39165	14994	64444530
General physical health deterioration	31.65	10.85	47	39161	204378	64255146
Bronchitis	31.23	10.85	140	39068	108603	64350921
Bladder pain	30.90	10.85	17	39191	1764	64457760
Cystitis	30.60	10.85	75	39133	42600	64416924
Tunnel vision	29.68	10.85	14	39194	1051	64458473
Drug interaction	28.05	10.85	119	39089	361964	64097560
Pericarditis	27.40	10.85	3	39205	62513	64397011
Deep vein thrombosis	26.96	10.85	131	39077	105051	64354473
Lactic acidosis	26.78	10.85	3	39205	61407	64398117
Pigment nephropathy	25.86	10.85	6	39202	43	64459481
Chronic kidney disease	25.16	10.85	85	39123	57834	64401690
Hand deformity	25.15	10.85	4	39204	62767	64396757
Skin laceration	24.38	10.85	49	39159	24368	64435156
Hepatitis infectious mononucleosis	24.21	10.85	7	39201	128	64459396
Bronchopulmonary aspergillosis allergic	24.13	10.85	14	39194	1608	64457916
Pemphigus	24.03	10.85	4	39204	60697	64398827
Migraine	23.80	10.85	88	39120	62589	64396935
Off label use	23.43	10.85	259	38949	632547	63826977
Gallbladder disorder	23.09	10.85	39	39169	16991	64442533
Genital ulceration	22.81	10.85	10	39198	633	64458891
Anxiety	22.68	10.85	205	39003	202444	64257080
Stevens-Johnson syndrome	22.26	10.85	58	39150	34191	64425333
Paranasal sinus discomfort	22.02	10.85	17	39191	3138	64456386
Nasal polyps	21.99	10.85	18	39190	3611	64455913
Gut fermentation syndrome	21.96	10.85	4	39204	6	64459518
Hepatic function abnormal	21.86	10.85	6	39202	64307	64395217
Wound secretion	21.82	10.85	21	39187	5211	64454313
Intentional overdose	21.62	10.85	14	39194	89930	64369594
Pemphigoid	20.69	10.85	32	39176	12954	64446570
Wound complication	20.67	10.85	18	39190	3930	64455594
Ear congestion	20.51	10.85	14	39194	2136	64457388
Sinus pain	20.39	10.85	15	39193	2574	64456950
Erythema	20.30	10.85	188	39020	186882	64272642
Systemic lupus erythematosus	20.18	10.85	11	39197	77601	64381923
Type I hypersensitivity	20.15	10.85	17	39191	3557	64455967
Sleep apnoea syndrome	19.88	10.85	51	39157	29781	64429743
Clostridium difficile colitis	19.68	10.85	48	39160	27175	64432349
Drug reaction with eosinophilia and systemic symptoms	19.65	10.85	75	39133	54142	64405382
Polymyalgia rheumatica	18.98	10.85	16	39192	3343	64456181
Therapeutic product effect incomplete	18.89	10.85	21	39187	103461	64356063
Familial periodic paralysis	18.87	10.85	6	39202	153	64459371
Depression	18.79	10.85	182	39026	183109	64276415
Implant site haematoma	18.76	10.85	6	39202	156	64459368
Rhabdomyolysis	18.59	10.85	17	39191	91709	64367815
Thrombocytopenia	18.28	10.85	72	39136	223729	64235795
Coma	18.04	10.85	16	39192	87599	64371925
Anaphylactic reaction	17.93	10.85	86	39122	68578	64390946
Febrile neutropenia	17.57	10.85	57	39151	187600	64271924
Product odour abnormal	17.28	10.85	10	39198	1143	64458381
Therapy cessation	17.15	10.85	51	39157	32438	64427086
Nephrolithiasis	17.14	10.85	62	39146	43621	64415903
Haemorrhoids thrombosed	17.09	10.85	6	39202	209	64459315
Skin cancer	17.01	10.85	28	39180	11946	64447578
Swollen tongue	16.70	10.85	53	39155	34901	64424623
Surgery	16.55	10.85	46	39162	28167	64431357
Localised infection	16.54	10.85	48	39160	30113	64429411
Toxic epidermal necrolysis	16.54	10.85	55	39153	37111	64422413
Diarrhoea	16.42	10.85	564	38644	722140	63737384
Kounis syndrome	16.26	10.85	14	39194	3011	64456513
Blister	16.06	10.85	94	39114	80873	64378651
Neutropenia	16.03	10.85	83	39125	239541	64219983
Lip swelling	15.82	10.85	49	39159	31858	64427666
Rash pruritic	15.80	10.85	73	39135	57331	64402193
Procedural pain	15.34	10.85	31	39177	15477	64444047
Oral pain	15.32	10.85	44	39164	27449	64432075
Complement factor C4 increased	15.28	10.85	5	39203	140	64459384
Circumoral oedema	15.24	10.85	6	39202	289	64459235
Tarsal tunnel syndrome	15.20	10.85	7	39201	498	64459026
Arthritis infective	15.14	10.85	20	39188	7010	64452514
Appetite disorder	14.88	10.85	19	39189	6442	64453082
Overdose	14.57	10.85	49	39159	159517	64300007
Skin ulcer	14.46	10.85	59	39149	43915	64415609
Middle ear effusion	14.45	10.85	11	39197	1988	64457536
Glossodynia	14.32	10.85	11	39197	64685	64394839
Diabetic retinal oedema	14.30	10.85	6	39202	341	64459183
Therapy interrupted	14.13	10.85	35	39173	20001	64439523
Agranulocytosis	14.10	10.85	3	39205	38226	64421298
Tubulointerstitial nephritis	13.99	10.85	46	39162	30863	64428661
Vanishing bile duct syndrome	13.83	10.85	9	39199	1268	64458256
Multiple lentigines syndrome	13.71	10.85	5	39203	195	64459329
Gastric disorder	13.70	10.85	44	39164	29153	64430371
Product dose omission issue	13.44	10.85	179	39029	194568	64264956
Actinic keratosis	13.20	10.85	16	39192	5149	64454375
Tinea infection	12.99	10.85	8	39200	1024	64458500
Hidradenitis	12.97	10.85	11	39197	2318	64457206
Biliary sepsis	12.92	10.85	9	39199	1419	64458105
Renal tubular necrosis	12.92	10.85	36	39172	22074	64437450
Ear pain	12.83	10.85	39	39169	25097	64434427
Intentional product use issue	12.82	10.85	24	39184	95340	64364184
Morbid thoughts	12.79	10.85	7	39201	719	64458805
Neovascular age-related macular degeneration	12.74	10.85	5	39203	239	64459285
Cholelithiasis	12.62	10.85	58	39150	45448	64414076
Ureteric obstruction	12.60	10.85	11	39197	2411	64457113
Lip haemorrhage	12.27	10.85	8	39200	1131	64458393
Polyomavirus-associated nephropathy	12.26	10.85	15	39193	4873	64454651
Bone marrow failure	12.17	10.85	7	39201	47945	64411579
Helicobacter duodenal ulcer	12.14	10.85	3	39205	29	64459495
Purpura senile	12.08	10.85	6	39202	505	64459019
Anaemia	12.06	10.85	160	39048	378520	64081004
Dysuria	11.95	10.85	54	39154	42003	64417521
Hepatic enzyme increased	11.79	10.85	40	39168	129903	64329621
Abscess drainage	11.77	10.85	6	39202	533	64458991
Pollakiuria	11.74	10.85	44	39164	31486	64428038
Blood creatine phosphokinase increased	11.69	10.85	11	39197	58547	64400977
Back pain	11.57	10.85	215	38993	249956	64209568
Malignant neoplasm progression	11.47	10.85	33	39175	112838	64346686
Tinnitus	11.38	10.85	46	39162	34087	64425437
Immune thrombocytopenia	11.35	10.85	27	39181	15039	64444485
Cardiogenic shock	11.07	10.85	3	39205	32424	64427100
Serotonin syndrome	11.07	10.85	5	39203	39277	64420247
Renal injury	10.93	10.85	27	39181	15402	64444122
Factor V inhibition	10.90	10.85	5	39203	352	64459172

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J01DB01	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS First-generation cephalosporins
FDA CS	M0003827	Cephalosporins
FDA EPC	N0000175488	Cephalosporin Antibacterial
CHEBI has role	CHEBI:36047	antibacterial drugs
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Acute otitis media	indication	3110003
Prostatitis	indication	9713002	DOID:14654
Infection of skin AND/OR subcutaneous tissue	indication	19824006
Pneumonia due to Streptococcus	indication	34020007
Streptococcal tonsillitis	indication	41582007
Klebsiella cystitis	indication	60867007
Infection of bone	indication	111253001
Escherichia coli urinary tract infection	indication	301011002
Proteus urinary tract infection	indication	301012009
Streptococcus pyogenes infection	indication	302809008
Bacterial urinary infection	indication	312124009
Infective otitis media	indication	312218008
Infectious disorder of joint	indication	363162000
Infection due to Staphylococcus aureus	indication	406602003
Osteomyelitis due to Staphylococcus aureus	indication	428783003
Klebsiella Prostatitis	indication
Proteus Prostatitis	indication
Haemophilus Influenzae Acute Otitis Media	indication
Streptococcus Osteomyelitis	indication
Staphylococcus Acute Otitis Media	indication
Moraxella Catarrhalis Acute Otitis Media	indication
Bacterial Mastitis	off-label use
Prevention of Bacterial Endocarditis	off-label use
Diabetic Foot Infection Due to Gram-Positive Bacteria	off-label use
Colitis	contraindication	64226004	DOID:0060180
Kidney disease	contraindication	90708001	DOID:557
Pseudomembranous enterocolitis	contraindication	397683000

🐶 Veterinary Drug Use

Species	Use	Relation
Dogs	Secondary superficial bacterial pyoderma caused by Staphylococcus pseudintermedius	Indication

🐶 Veterinary products

Product	Applicant	Ingredients
Rilexine Chewable Tablets	Virbac AH Inc.	1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.77	acidic
pKa2	13.53	acidic
pKa3	7.67	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Solute carrier family 15 member 2	Transporter	Q16348	S15A2_HUMAN		IC50	4.38	WOMBAT-PK
Bacterial penicillin-binding protein	Enzyme		PBPA_ECOLI PBPB_ECOLI DACC_ECOLI PBP2_ECOLI FTSI_ECOLI DACA_ECOLI DACB_ECOLI	INHIBITOR			CHEMBL	CHEMBL
Penicillin-binding protein 3	Enzyme		PBPC_BACSU				WOMBAT-PK

External reference:

ID	Source
4018893	VUID
N0000179741	NUI
D00263	KEGG_DRUG
23325-78-2	SECONDARY_CAS_RN
105879-42-3	SECONDARY_CAS_RN
1299782	RXNORM
4018891	VANDF
4018893	VANDF
C0007716	UMLSCUI
CHEBI:3534	CHEBI
CHEMBL1727	ChEMBL_ID
CHEMBL1200544	ChEMBL_ID
DB00567	DRUGBANK_ID
4832	IUPHAR_LIGAND_ID
OBN7UDS42Y	UNII
27447	PUBCHEM_CID
4393	MMSL
d00096	MMSL
002716	NDDF
002717	NDDF
387304003	SNOMEDCT_US
54062005	SNOMEDCT_US
54887004	SNOMEDCT_US
785690001	SNOMEDCT_US
D002506	MESH_DESCRIPTOR_UI
CHEMBL1200366	ChEMBL_ID
2400	INN_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-2238	TABLET	250 mg	ORAL	ANDA	19 sections
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-2238	TABLET	250 mg	ORAL	ANDA	19 sections
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-2240	TABLET	500 mg	ORAL	ANDA	19 sections
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-2240	TABLET	500 mg	ORAL	ANDA	19 sections
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-3145	CAPSULE	250 mg	ORAL	ANDA	23 sections
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-3145	CAPSULE	250 mg	ORAL	ANDA	23 sections
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-3147	CAPSULE	500 mg	ORAL	ANDA	23 sections
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-3147	CAPSULE	500 mg	ORAL	ANDA	23 sections
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-4175	POWDER, FOR SUSPENSION	125 mg	ORAL	ANDA	23 sections
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-4175	POWDER, FOR SUSPENSION	125 mg	ORAL	ANDA	23 sections
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-4177	POWDER, FOR SUSPENSION	250 mg	ORAL	ANDA	23 sections
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-4177	POWDER, FOR SUSPENSION	250 mg	ORAL	ANDA	23 sections
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9769	SUSPENSION	125 mg	ORAL	ANDA	24 sections
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9770	SUSPENSION	250 mg	ORAL	ANDA	24 sections
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9897	CAPSULE	500 mg	ORAL	ANDA	23 sections
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9898	CAPSULE	250 mg	ORAL	ANDA	23 sections
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	0440-1243	CAPSULE	250 mg	ORAL	ANDA	19 sections
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	0440-7244	CAPSULE	500 mg	ORAL	ANDA	23 sections
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	10544-004	CAPSULE	500 mg	ORAL	ANDA	23 sections
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	10544-013	CAPSULE	500 mg	ORAL	ANDA	24 sections
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	10544-020	CAPSULE	500 mg	ORAL	ANDA	23 sections
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	10544-021	CAPSULE	250 mg	ORAL	ANDA	24 sections
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	10544-025	CAPSULE	500 mg	ORAL	ANDA	24 sections
cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	10544-057	CAPSULE	500 mg	ORAL	ANDA	24 sections
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	10544-066	CAPSULE	250 mg	ORAL	ANDA	19 sections
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	10544-082	CAPSULE	500 mg	ORAL	ANDA	21 sections
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	10544-142	CAPSULE	250 mg	ORAL	ANDA	23 sections
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	10544-503	CAPSULE	500 mg	ORAL	ANDA	13 sections
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	10544-529	CAPSULE	500 mg	ORAL	ANDA	22 sections
Cephalexin	HUMAN PRESCRIPTION DRUG LABEL	1	10544-617	CAPSULE	500 mg	ORAL	ANDA	19 sections